Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Small Pharma Inc
(OP:
DMTTF
)
N/A
UNCHANGED
Last Price
Updated: 3:59 PM EDT, Oct 20, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Small Pharma Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Small Pharma Reports Fiscal First Quarter 2024 Highlights
July 27, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
July 11, 2023
First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic...
Via
Benzinga
Small Pharma Implements Costs Cut: New R&D Strategy And Management Team Change
July 05, 2023
Together with reporting its annual financial results and pipeline update, short-acting psychedelics developer Small Pharma Inc. (OTCQB: DMTTF) stated its intentions to
Via
Benzinga
Small Pharma Announces SPL028 R&D Strategy Update
July 05, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Small Pharma Announces Management Team Change
July 05, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
July 04, 2023
World's Largest Psychedelics Conference Boasts 12K Attendees
Via
Benzinga
Small Pharma Implements Cost-Cutting Strategy To Reduce Cash Burn As Trial Progresses
June 29, 2023
UK-based biotech firm Small Pharma Inc. (OTCQB: DMTTF) shared its financial outcomes for the fiscal year ended Feb. 28, plus pipeline updates. Highlights:
Via
Benzinga
Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights
June 28, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
May 31, 2023
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics...
Via
Benzinga
Small Pharma's IP Portfolio Grows With Numerous Approved Patent Applications Around The World
May 26, 2023
U.K.-based short-acting psychedelics developer Small Pharma Inc. (OTCQB: DMTTF) has been working hard on securing a proprietary IP throughout North America, Australasia and Europe.
Via
Benzinga
Small Pharma Announces Significant Developments In Intellectual Property Portfolio
May 25, 2023
5 new patent grants, 3 expected upcoming patent grants, and 8 notices of allowance in key international jurisdictions
From
Small Pharma Inc.
Via
GlobeNewswire
Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology
May 03, 2023
Chief Medical and Scientific Officer, Dr. Carol Routledge, will deliver a poster presentation on data from the Company’s SPL026 Phase IIa clinical trial in patients with Major Depressive Disorder
From
Small Pharma Inc.
Via
GlobeNewswire
DMT For Major Depression Shows Remarkable Benefits After Six-Month Trial
April 04, 2023
Short-acting psychedelics company Small Pharma Inc.
Via
Benzinga
Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026
April 04, 2023
Approximately two-thirds of trial patients with Major Depressive Disorder achieving remission following SPL026 treatment sustained remission to six-months
From
Small Pharma Inc.
Via
GlobeNewswire
EXCLUSIVE: NYC Ketamine Center Co-Founder On Prices, Insurance, Competition & Expansion
March 21, 2023
This is the third article of a three-part series, you can find the first and
Via
Benzinga
Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
March 13, 2023
Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial
Via
Benzinga
Major Psychedelics VC & EFT Directors Will Share Valuable Insights At Upcoming Benzinga Event
March 13, 2023
The Benzinga Psychedelics Capital Conference (PCC) is rapidly becoming the place to be for all those interested or involved in the space. In addition to being the place where deals are done, you'll...
Via
Benzinga
Small Pharma Inc: Positive Clinical Data For Major Depressive Disorder, Upcoming Virtual Roundtable
March 08, 2023
Short-acting psychedelics biotech company Small Pharma Inc. (OTCQB: DMTTF) shared positive outcomes from its Phase 2a study of SPL026, the first placebo-controlled trial of the DMT-based short-duration...
Via
Benzinga
Small Pharma to Host Virtual Roundtable Event with Key Opinion Leaders in Psychiatry
March 07, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results
March 07, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Small Pharma to Present at Cowen’s 43rd Annual Health Care Conference
March 01, 2023
Company will also host a cocktail reception on Tuesday, March 7
From
Small Pharma Inc.
Via
GlobeNewswire
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
February 21, 2023
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and...
Via
Benzinga
Short-Acting Psychedelics: DMT-Based Drug Therapy Gets Tested In New Clinical Trial
February 15, 2023
Psychedelics biotech company Small Pharma Inc. (OTCQB: DMTTF) has dosed the first subject in its first-in-human clinical trial assessing proprietary DMT drug SPL028 paired with supportive therapy.
Via
Benzinga
First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028
February 15, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Race Is On For Psychedelic DMT-Related Compounds, Small Pharma, Inc To Issue Two New Patents
February 01, 2023
After the positive results provided by its clinical trial assessing novel DMT’s effects on patients with Major Depressive Disorder (MDD), psychedelics biotech Small Pharma Inc.
Via
Benzinga
Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue
February 01, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Small Pharma, Inc's Psychedelics For Major Depression Trial Results And Q1 Earnings
January 25, 2023
Short-acting psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF)’s proprietary intravenous (IV) DMT-based drug SPL026 delivered positive topline results in a Phase 2a trial for the treatment of Major...
Via
Benzinga
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
January 25, 2023
Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental
Via
PressReach
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
January 25, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder
January 25, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.